FindTrial
Sign In

ADCT-402

DRUG2 trials

Sponsors

ADC Therapeutics S.A.

Conditions

Acute Lymphoblastic LeukemiaBurkitt's LymphomaChronic Lymphocytic LeukemiaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, Marginal ZoneNon-Hodgkin Lymphoma

Phase 1

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
CompletedNCT02669017
ADC Therapeutics S.A.Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Follicular +6
Start: 2016-03-31End: 2019-02-21Updated: 2021-05-19
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
TerminatedNCT02669264
ADC Therapeutics S.A.Acute Lymphoblastic Leukemia
Start: 2016-03-31End: 2018-07-03Updated: 2021-05-24

Related Papers

QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy
npj Systems Biology and Applications2025-06-111 citations
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
2021-12-106 citations
Abstract 1367: Relationship between exposure and safety/efficacy of loncastuximab tesirine (Lonca) in B-cell non-Hodgkin lymphoma (B-NHL)
Cancer Research2021-07-01
Abstract 1366: Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL)
Cancer Research2021-07-01
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Blood2020-11-20165 citations
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Blood Advances2020-02-0353 citations
ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Hematological Oncology2019-06-014 citations
Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study
Blood2018-11-2913 citations
Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood2018-11-299 citations
Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma
Blood2017-12-077 citations
FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL
Hematological Oncology2017-06-017 citations
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
Journal of Clinical Oncology2016-05-203 citations